Details for Patent: 11,389,447
✉ Email this page to a colleague
Which drugs does patent 11,389,447 protect, and when does it expire?
Patent 11,389,447 protects CABENUVA KIT and is included in one NDA.
This patent has thirty-six patent family members in thirty-one countries.
Summary for Patent: 11,389,447
| Title: | Aqueous suspensions of TMC278 |
| Abstract: | This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection. |
| Inventor(s): | Baert; Lieven Elvire Colette (Bruges, BE), Dries; Willy Albert Maria Carlo (Merksplas, BE), Schueller; Laurent Bruno (Antwerp, BE), Francois; Marc Karel Jozef (Kapellen, BE), Van Remoortere; Peter Jozef Maria (Kapellen, BE) |
| Assignee: | Janssen Sciences Ireland Unlimited Company (County Cork, IE) |
| Application Number: | 14/964,297 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,389,447
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY | ⤷ Sign Up | ||||
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-002 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,389,447
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 06115398 | Jun 23, 2006 | |
International Family Members for US Patent 11,389,447
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2618 | ⤷ Sign Up | |||
| Argentina | 061620 | ⤷ Sign Up | |||
| Australia | 2007262941 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
